Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells therapy (Children'S National Research Institute)

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameSelective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells therapy (Children'S National Research Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD276Anti-Melanoma antigen preferentially expressed in tumorsTGF antagonists
TargetsCD276 antigenMelanoma antigen preferentially expressed in tumorsTransforming growth factor beta
Therapy Area/IndicationsNeuroblastomaRhabdomyosarcomaSarcoma, Ewing +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChildren'S National Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesChildren'S National Research Institute
Inactive CompaniesN/A
Active IndicationsNeuroblastomaRhabdomyosarcomaSarcoma, Ewing +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A